Comparative Pharmacology
Head-to-head clinical analysis: FOAMCOAT versus NEOSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOAMCOAT versus NEOSPORIN.
FOAMCOAT vs NEOSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic